Immuno-oncology (I-O) therapies have been extensively explored in recent years, particularly immune checkpoint inhibitors (ICIs) such as programmed cell death protein 1 (PD-1) and PD-ligand 1 (PD-L1) inhibitors. Robust and stable animal models are essential for advancing preclinical research and addressing challenges such as low response rates to anti-PD-1/PD-L1 therapies and drug resistance.
GemPharmatech has developed a human peripheral blood mononuclear cell (PBMC)-based humanized xenograft model. In this newly established model, human PBMCs are mixed with human tumor cell lines (including A-431 epidermoid carcinoma) and inoculated subcutaneously into the right flank of immunodeficient NCG mice. This PBMCs-cancer cell lines mixed injection model of NCG mice provides a valuable opportunity to evaluate the in vivo efficacy of immune checkpoint inhibitors.